Atlas Trials

Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds

Clinical trial NCT04240886 · TERMINATED

Trial details

NCT number
NCT04240886
Sponsor
Basilea Pharmaceutica
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Invasive Fungal Infections
Start date
2020-01-04
Primary completion
2022-03-29
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.